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Summary
 Background Epstein-Barr virus (EBV) reactivation is a frequent event (5–20%) following all-
ogeneic stem cell transplantation (allo-SCT) that may progress to life-threaten-
ing EBV-lymphoproliferative disease (EBV-LPD).
 Aim To present data relevant to incidence, diagnosis and contemporary management 
of Epstein-Barr virus (EBV) reactivation in children undergoing allogeneic hae-
matopoietic stem cell transplantation.
 Materials/Methods A review of PubMed references based on evidence-based recommendations and 
own experience
 Results Epstein-Barr virus (EBV) reactivation is a frequent event (5–20%) following allo-
geneic stem cell transplantation that may progress to life-threatening EBV-lympho-
proliferative disease (EBV-LPD), especially after T-cell depletion in vitro and/or 
in vivo. Clinical symptoms are frequently lacking in the early stages of EBV reac-
tivation. The introduction of real-time polymerase chain reaction (RQ-PCR) sev-
eral years ago has provided a powerful tool to monitor EBV reactivation in still 
asymptomatic allo-SCT recipients and to predict increased risk of developing EBV-
LPD. Recently, evidence has been provided that EBV-DNA load guided preemp-
tive treatment with B cell depleting CD20 monoclonal antibodies (Rituximab®) 
is effective in preventing EBV-LPD in allo-SCT recipients at high risk.
 Conclusions We propose that simultaneous and on-line analysis of both EBV-DNA load and T 
cell recovery will improve the identiﬁ cation of patients at high risk for EBV-LPD. 
These patients will probably beneﬁ t most from pre-emptive interventions.
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BACKGROUND
Allogeneic stem cell transplantation is increasing-
ly used for the treatment of various benign and 
malignant haematological disorders, primary im-
munodeﬁ ciencies and metabolic diseases.
Epstein-Barr virus (EBV) reactivation is a fre-
quent event (5–20%) following allogeneic stem 
cell transplantation (allo-SCT) that may progress 
to life-threatening EBV-lymphoproliferative dis-
ease (EBV-LPD)
AIM
To present data relevant to incidence, diagno-
sis and contemporary management of Epstein-
Barr virus (EBV) reactivation in children un-
dergoing allogeneic haematopoietic stem cell 
transplantation.
MATERIALS AND METHODS
References were retrieved using the online 
database of the National Library of Medicine 
(PubMed; http://www.ncbi.nlm.nih.gov/PubMed). 
Terms used included: EBV reactivation, EBV-lym-
phoproliferative disease, allogeneic HSCT. The 
retrieved references were supplemented by ref-
erences from the author’s own database.
RESULTS
Allogeneic stem cell transplantation is increasing-
ly used for the treatment of various benign and 
malignant haematological disorders, primary im-
munodeﬁ ciencies and metabolic diseases
As a result of more accurate HLA typing, im-
proved T cell depletion by graft manipulation in 
vitro and in vivo, and progress in supportive care, 
SCTs with unrelated and mismatched donors 
are increasingly performed and currently repre-
sent around 70% of paediatric SCTs. Inevitably, 
these types of SCTs are characterized by a pro-
longed period of immune incompetence post 
transplant. This lack of immune surveillance re-
sults in increased frequency, duration and sever-
ity of reactivation of human herpes viruses and 
adenoviruses.
Epstein-Barr virus (EBV) reactivation is a fre-
quent event (5–20%) following allogeneic stem 
cell transplantation (allo-SCT) that may progress 
to life-threatening EBV-lymphoproliferative dis-
ease (EBV-LPD). Risk factors for EBV reactivation 
and subsequent EBV-LPD include the use of un-
related or mismatched family donors, T-cell de-
pletion in vitro, anti-thymocyte globulin (ATG) 
and non-myeloablative SCTs [1].
Clinical symptoms are frequently lacking in the 
early stages of EBV reactivation and are often 
only recognized in the later stages where they co-
incide with progressive EBV-LPD. Similar to the 
strategy employed for the detection of CMV vi-
raemia (DNA-emia) attempts were made to use 
molecular techniques for the early recognition 
of EBV reactivation. The introduction of real-
time polymerase chain reaction (RQ-PCR) sev-
eral years ago has provided a powerful tool to 
monitor EBV reactivation in still asymptomatic 
allo-SCT recipients and to predict increased risk 
of developing EBV-LPD [2,3].
DISCUSSION
Until recently, clinical management of EBV-LPD 
was largely restricted to prophylactic strategies, 
i.e. B-cell depletion of the graft, and therapeu-
tic interventions in the late stages of EBV disease 
through restoration of T-cellular immunity by 
means of donor lymphocyte infusion (DLI) or 
administration of EBV-speciﬁ c cytotoxic T lym-
phocytes (CTL). Although effective in some cas-
es, DLI frequently resulted in an unfavourable 
outcome, whereas clinical grade CTL were only 
available in few specialized centres.
Recently, evidence has been provided that EBV-
DNA load guided preemptive treatment with 
B cell depleting CD20 monoclonal antibodies 
(Rituximab®) is effective in preventing EBV-LPD 
in allo-SCT recipients at high risk [4].
Although effective in preventing EBV-LPD, 
preemptive treatment based on EBV-DNA load 
as a single parameter deﬁ nitely results in unnec-
essary treatment in a signiﬁ cant number of pa-
tients. Since EBV-LPD only occurs in the absence 
of adequate T cell immunity, we and others ret-
rospectively analysed (EBV-speciﬁ c) T cell recon-
stitution during EBV reactivation in paediatric 
allo-SCT recipients who had received preemptive 
treatment with CD20 antibodies (Rituximab®) 
[5,6]. Rapid reconstitution of CD4+ and CD8+ T 
cells and particularly EBV-speciﬁ c CD8+ T cells 
was documented in a signiﬁ cant number of EBV 
reactivation episodes, suggesting that EBV reac-
tivation might have been controlled without ad-
ditional help of Rituximab. We obtained sup-
port for this hypothesis based on the outcome 
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in a prospectively monitored cohort of SCT re-
cipients with EBV reactivation [6].
CONCLUSIONS
Based on the aforementioned ﬁ ndings we pro-
pose that simultaneous and on-line analysis of 
both EBV-DNA load and T cell recovery will im-
prove the identiﬁ cation of patients at high risk 
for EBV-LPD. These patients will probably bene-
ﬁ t most from preemptive interventions, especial-
ly treatment with Rituximab. These ﬁ ndings can 
probably be extrapolated to other viral reactiva-
tions (esp CMV and AdV) that occur during the 
period of immune reconstitution postSCT.
REFERENCES:
 1. Gottschalk S et al: Post-transplant lymphoprolif-
erative disorders. Ann Rev Med, 2005; 56: 29–44
 2. van Esser JW et al: Epstein-Barr virus (EBV) reac-
tivation is a frequent event after allogeneic stem 
cell transplantation (SCT) and quantitatively pre-
dicts EBV-lymphoproliferative disease following 
T-cell – depleted SCT. Blood, 2001; 98: 972–8
 3. Lankester AC et al: Epstein-Barr virus (EBV)-DNA 
quantiﬁ cation in pediatric allogenic stem cell re-
cipients: prediction of EBV-associated lymphopro-
liferative disease. Blood, 2002; 99: 2630–1
 4. van Esser J et al: Prevention of Epstein-Barr virus-
lymphoproliferative disease by molecular moni-
toring and preemptive rituximab in high-risk pa-
tients after allogeneic stem cell transplantation. 
Blood, 2002; 99: 4364–9
 5. Meij P et al: Impaired recovery of Epstein-Barr virus 
(EBV) – speciﬁ c CD8+ T lymphocytes after partial-
ly T-depleted allogeneic stem cell transplantation 
may identify patients at very high risk for progres-
sive EBV reactivation and lymphoproliferative dis-
ease. Blood, 2003; 101: 4290–7
 6. Annels NE et al: Management of Epstein-Barr vi-
rus (EBV) reactivation after allogeneic stem cell 
transplantation by simultaneous analysis of EBV 
DNA load and EBV-speciﬁ c T cell reconstitution. 
Clin Infect Dis, 2006; 42: 1743–8
Rep Pract Oncol Radiother, 2007; 12(3): 163-165 Lankester AC – EBV reactivation, allogeneic HSCT
165
